Intrommune Therapeutics
PrivateLast Round
Series A
Jun 9, 2021
Est. Valuation
$15.11M
Total Funding Raised
$5.51M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Intrommune Therapeutics operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series A round in June 2021.
Intrommune Therapeutics is a biotechnology company that is developing a treatment platform for food allergies using oral mucosal immunotherapy (OMIT) delivered through a specially formulated toothpaste.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Intrommune Therapeutics Comparables
Compare Intrommune Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Moonlight Therapeutics | 81% | |
| Prota Therapeutics | 78% | |
| InnoUp Farma | 78% |
For institutional investors. Book with your work email.
Intrommune Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 9, 2021 | ||||
| Crowdfunding | Apr 12, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Intrommune Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Chemical Angel Network | Series A |
| Robin Hood Ventures | Series A |
| Red Bear Ventures | Series A |
| Timberline Holdings | Series A |
| Netcapital | Crowdfunding |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 41% MoM.
- Aug 21, 2026
Monthly visitors increased 31% MoM.
For institutional investors. Book with your work email.
Intrommune Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Intrommune Therapeutics's valuation, stock price, and market status.
Is Intrommune Therapeutics a public or private company?
Intrommune Therapeutics is a private company.
What is the current stock price of Intrommune Therapeutics?
Intrommune Therapeutics is a private company, so its shares have no public market price. Caplight tracks Intrommune Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Intrommune Therapeutics worth (valuation)?
Intrommune Therapeutics's valuation is estimated at $15.1M based on funding round data.
Can I buy Intrommune Therapeutics stock?
Intrommune Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Intrommune Therapeutics's last funding round?
Intrommune Therapeutics's most recent funding round was Series A on June 9, 2021.
Who are the main investors in Intrommune Therapeutics?
Key investors in Intrommune Therapeutics include Red Bear Ventures.
Will Intrommune Therapeutics IPO soon?
No public IPO plans have been announced for Intrommune Therapeutics.
How can I track Intrommune Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Intrommune Therapeutics's shares on secondary markets.